GSEP
PRCT icon

Golden State Equity Partners’s Procept Biorobotics PRCT Stock Holding History

Golden State Equity Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45
Closed -$1.13K – 1370
2026
Q1 		$1.13K Buy
+45
New +$1.27K ﹤0.01% 1770

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Golden State Equity Partners's PRCT Position: Q2 2026 in Review

Golden State Equity Partners sold out of Procept Biorobotics (PRCT) in Q2 2026, closing a stake of 45 shares — an estimated $1.13K sold.

Golden State Equity Partners first reported a position in PRCT in Q1 2026 and held it in 1 quarter. The position peaked at $1.13K in Q1 2026. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Golden State Equity Partners reported no remaining Procept Biorobotics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 45 Procept Biorobotics shares in Q2 2026, an estimated $1.13K.
  • Golden State Equity Partners first reported a position in Procept Biorobotics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Procept Biorobotics position peaked at $1.13K in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.